Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kötter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA. Tyndall AJ, et al. Among authors: bannert b. Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264. Epub 2010 Jun 15. Ann Rheum Dis. 2010. PMID: 20551155 Free article.
Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis.
Kollert F, Christoph S, Probst C, Budweiser S, Bannert B, Binder M, Sehnert B, Voll RE, Warnatz K, Zissel G, Walker UA, Prasse A, Saalbach A. Kollert F, et al. Among authors: bannert b. Arthritis Care Res (Hoboken). 2013 Feb;65(2):281-7. doi: 10.1002/acr.21799. Arthritis Care Res (Hoboken). 2013. PMID: 22807289 Free article.
Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
Heijnen IA, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V, Kumánovics G, Becker MO, Vanthuyne M, Simsek I, Bocelli-Tyndall C, Walker UA. Heijnen IA, et al. Among authors: bannert b. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):96-102. Epub 2012 Oct 24. Clin Exp Rheumatol. 2013. PMID: 23101460
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators. Wu W, et al. Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9. Ann Rheum Dis. 2019. PMID: 30852552 Free PMC article.
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.
Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C. Bühler S, et al. Among authors: bannert b. Rheumatology (Oxford). 2019 Sep 1;58(9):1585-1596. doi: 10.1093/rheumatology/kez045. Rheumatology (Oxford). 2019. PMID: 30877773 Clinical Trial.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group. Clowse ME, et al. Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856. Arthritis Rheumatol. 2017. PMID: 27598855 Free PMC article. Clinical Trial.
Impact of tofacitinib treatment on human B-cells in vitro and in vivo.
Rizzi M, Lorenzetti R, Fischer K, Staniek J, Janowska I, Troilo A, Strohmeier V, Erlacher M, Kunze M, Bannert B, Kyburz D, Voll RE, Venhoff N, Thiel J. Rizzi M, et al. Among authors: bannert b. J Autoimmun. 2017 Feb;77:55-66. doi: 10.1016/j.jaut.2016.10.005. Epub 2016 Oct 26. J Autoimmun. 2017. PMID: 27793425
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y, Marsal S, Sanmartí R, Nurmohamed MT, Griffiths H, Peichl P, Bannert B, Chartier M, Connolly SE, Lozenski K, Rauch C. Alten R, et al. Among authors: bannert b. Clin Rheumatol. 2022 Aug;41(8):2361-2373. doi: 10.1007/s10067-022-06176-1. Epub 2022 May 10. Clin Rheumatol. 2022. PMID: 35536413 Free PMC article.
25 results